Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Logothetis

Showing results (801-810 of 1,104) with videos related to

Pageof 111
Sort By:
Journal of the National Cancer Institute|September 7, 2006
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer modelYuki Ishii, Andreja Pirkmaier, James V Alvarez, et al.
The Journal of Biological Chemistry|January 11, 2018
Hydrogen sulfide inhibits Kir2 and Kir3 channels by decreasing sensitivity to the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>)Junghoon Ha, Yu Xu, Takeharu Kawano, et al.
The Journal of Biological Chemistry|May 20, 2014
Structural-functional analysis of the third transmembrane domain of the corticotropin-releasing factor type 1 receptor: role in activation and allosteric antagonismKaterina Spyridaki, Minos-Timotheos Matsoukas, Arnau Cordomi, et al.
European Journal of Haematology|November 20, 2023
Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective studyDamian A Laber, Parth C Patel, Constantine N Logothetis, et al.
The Journal of Biological Chemistry|May 7, 2022
A novel small-molecule selective activator of homomeric GIRK4 channelsMeng Cui, Keman Xu, Kirin D Gada, et al.
Nature|May 20, 2005
Lack of long-term cortical reorganization after macaque retinal lesionsStelios M Smirnakis, Alyssa A Brewer, Michael C Schmid, et al.
The Lancet. Oncology|October 19, 2007
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient dataKarim Fizazi, Aurelie Le Maitre, Gary Hudes, et al.
Genome Biology|July 8, 2020
Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencingNaveen Ramesh, Emi Sei, Pei Ching Tsai, et al.
Carcinogenesis|August 2, 2002
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cellsLuis A Martinez, Jun Yang, Elba S Vazquez, et al.
Cancer|January 28, 2003
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinomaDanai D Daliani, Vasily Assikis, Shi-Ming Tu, et al.
Pageof 111

Showing results (801-810 of 1,104) with videos related to

Sort By:
Pageof 111
Journal of the National Cancer Institute|September 7, 2006
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer modelYuki Ishii, Andreja Pirkmaier, James V Alvarez, et al.
The Journal of Biological Chemistry|January 11, 2018
Hydrogen sulfide inhibits Kir2 and Kir3 channels by decreasing sensitivity to the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>)Junghoon Ha, Yu Xu, Takeharu Kawano, et al.
The Journal of Biological Chemistry|May 20, 2014
Structural-functional analysis of the third transmembrane domain of the corticotropin-releasing factor type 1 receptor: role in activation and allosteric antagonismKaterina Spyridaki, Minos-Timotheos Matsoukas, Arnau Cordomi, et al.
European Journal of Haematology|November 20, 2023
Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective studyDamian A Laber, Parth C Patel, Constantine N Logothetis, et al.
The Journal of Biological Chemistry|May 7, 2022
A novel small-molecule selective activator of homomeric GIRK4 channelsMeng Cui, Keman Xu, Kirin D Gada, et al.
Nature|May 20, 2005
Lack of long-term cortical reorganization after macaque retinal lesionsStelios M Smirnakis, Alyssa A Brewer, Michael C Schmid, et al.
The Lancet. Oncology|October 19, 2007
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient dataKarim Fizazi, Aurelie Le Maitre, Gary Hudes, et al.
Genome Biology|July 8, 2020
Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencingNaveen Ramesh, Emi Sei, Pei Ching Tsai, et al.
Carcinogenesis|August 2, 2002
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cellsLuis A Martinez, Jun Yang, Elba S Vazquez, et al.
Cancer|January 28, 2003
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinomaDanai D Daliani, Vasily Assikis, Shi-Ming Tu, et al.
Pageof 111